ARYx Therapeutics
Pharmaceutical company focused on retrometabolic drug designing and improving the safety of oral therapies for chronic diseases
About ARYx Therapeutics
ARYx Therapeutics, Inc. was a biopharmaceutical company founded in 1997 by Peter Milner, with its headquarters in Fremont, California. The company focused on developing a portfolio of internally discovered product candidates. Its business model was centered on its proprietary RetroMetabolic Drug Design technology, which aimed to create structurally unique molecules. This technology was designed to retain the efficacy of well-established, commercially successful drugs while metabolizing them through a safer pathway to avoid known adverse side effects.
The company's clinical development pipeline included several products. Naronapride (ATI-7505) was a prokinetic agent for treating various gastrointestinal disorders. Tecarfarin (ATI-5923) was developed as an oral anticoagulant. Budiodarone (ATI-2042) was an oral anti-arrhythmic agent for atrial fibrillation, and ATI-9242 was an agent for treating schizophrenia and other psychiatric disorders. The company went public with an IPO on November 8, 2007. Over its lifetime, ARYx Therapeutics raised a total of $226 million in funding.
Despite its product pipeline, the company faced significant challenges. In October 2010, ARYx received a notice of non-compliance from NASDAQ for failing to meet the minimum market capitalization requirement. Subsequently, in December 2010, its stock listing was transferred from the NASDAQ Global Market to the NASDAQ Capital Market. The company's situation worsened, and in March 2011, ARYx Therapeutics announced it would be closing its operations. This decision was attributed to a delay by the FDA in providing guidance on a critical trial design for its gastrointestinal drug, naronapride, which led to the withdrawal of a planned financing from investors. The company laid off its remaining executives, who were then hired as consultants in a final attempt to move forward. Ultimately, the company terminated all employees in 2010 and became a shell company before liquidating in May 2013. The liquidation was not expected to provide any cash return to stockholders, with assets going to secured creditors.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2007
News
Open roles
ARYx Therapeutics in the Fremont ecosystem
The ARYx Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about ARYx Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See ARYx Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.










